These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 6985497)

  • 21. Increasing the dosage of vincristine: a clinical and pharmacokinetic study of continuous-infusion vincristine in children with central nervous system tumors.
    Kellie SJ; Koopmans P; Earl J; Nath C; Roebuck D; Uges DR; De Graaf SS
    Cancer; 2004 Jun; 100(12):2637-43. PubMed ID: 15197807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of interleukin-12 with lung cancer and malignant lymphoma undergoing autologous peripheral blood stem cell transplantation.
    Yoshimura C; Nomura S; Kanazawa S; Kuwana M; Yamaguchi K; Fukuhara S
    J Cancer Res Clin Oncol; 2002 Jan; 128(1):29-36. PubMed ID: 11862469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recovery.
    Ballester OF; Agaliotis DP; Hiemenz JW; Janssen WE; Fields KK; Zorksy PE; Goldstein SC; Perkins JB; Elfenbein GJ
    Bone Marrow Transplant; 1996 Jul; 18(1):9-14. PubMed ID: 8831989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
    Miller AA; Rosner GL; Ratain MJ; Hollis DR; Green MR; Schilsky RL
    Clin Cancer Res; 1997 May; 3(5):719-25. PubMed ID: 9815741
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma.
    Blayney DW; McGuire BW; Cruickshank SE; Johnson DH
    Oncologist; 2005 Feb; 10(2):138-49. PubMed ID: 15709216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
    Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Increased blood cell destruction during vigorous regeneration of bone marrow after CAMBO-VIP chemotherapy for non-Hodgkin's lymphoma].
    Maruyama F; Ezaki K; Okamoto M; Miyazaki H; Wakita M; Nomura T; Tsuzuki M; Kojima H; Sobue R; Matsui T
    Rinsho Ketsueki; 1994 Feb; 35(2):114-9. PubMed ID: 7511181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
    Scheid C; Pettengell R; Ghielmini M; Radford JA; Morgenstern GR; Stern PL; Crowther D
    Bone Marrow Transplant; 1995 Jun; 15(6):901-6. PubMed ID: 7581089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
    Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequential high dose-density chemotherapy with two active regimens for advanced small cell lung cancer.
    Vigani A; Pensa F; Vaira F; Bancalari L; Cordani S; Maggiani R; Canessa P; Pronzato P
    Anticancer Res; 2000; 20(5C):4015-8. PubMed ID: 11268494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
    de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J
    Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. No salvage using high-dose chemotherapy plus/minus reirradiation for relapsing previously irradiated medulloblastoma.
    Massimino M; Gandola L; Spreafico F; Biassoni V; Luksch R; Collini P; Solero CN; Simonetti F; Pignoli E; Cefalo G; Poggi G; Modena P; Mariani L; Potepan P; Podda M; Casanova M; Pecori E; Acerno S; Ferrari A; Terenziani M; Meazza C; Polastri D; Ravagnani F; Fossati-Bellani F
    Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1358-63. PubMed ID: 19019566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
    Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
    J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Middle-high dose of cyclophosphamide or conventional routine chemotherapy with increased dose of cyclophosphamide combined with G-CSF for mobilizing peripheral blood progenitor cells in patients with tumor].
    Lu DP; Liu KY; Guo NL; Shi YK; He XH; Lou FD; Da WM; Zhang BL; Wang LX; Ke XY
    Zhonghua Xue Ye Xue Za Zhi; 2003 Feb; 24(2):68-70. PubMed ID: 12697098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MOPP/ABV/CAD chemotherapy with and without recombinant human granulocyte-macrophage colony stimulating factor in untreated, unfavorable prognosis Hodgkin's disease.
    Riccardi A; Gobbi P; Danova M; Giordano M; Pieresca C; Bertoloni D; Brugnatelli S; Ascari E
    Haematologica; 1993; 78(1):44-8. PubMed ID: 7684012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of cyclophosphamide on advanced lung cancer and the hematological toxicity of large, intermittent intravenous doses.
    Bergsagel DE; Robertson GL; Hasselback R
    Can Med Assoc J; 1968 Mar; 98(11):532-8. PubMed ID: 5643297
    [No Abstract]   [Full Text] [Related]  

  • 37. [Correlation between the number of monocytes and granulocytes in the peripheral blood in lung cancer patients].
    Sukhanov IuS
    Probl Gematol Pereliv Krovi; 1976 Dec; 21(12):23-6. PubMed ID: 1024199
    [No Abstract]   [Full Text] [Related]  

  • 38. [Staining of blood smears with rivanol in patients suffering from bronchogenic neoplasms].
    Czerny K
    Gegenbaurs Morphol Jahrb; 1975; 121(2):209-13. PubMed ID: 54278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment of lung cancer with Endoxan, with reference to the effect of massive intermittent administration].
    Matsuda M; Nishihara H; Komatsu T; Hattori S; Terasawa T
    Saishin Igaku; 1967 Aug; 22(8):1808-20. PubMed ID: 6081168
    [No Abstract]   [Full Text] [Related]  

  • 40. [Effect of endoxan on changes of cellular elements in peripheral blood].
    Sadliński C; Stadnik J; Wodarczyk D; Biskupek H
    Pol Tyg Lek; 1969 Oct; 24(47):1811-3. PubMed ID: 5363089
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.